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Acute toxicity was defined as up to 18 weeks from the start 
of RT and was assessed using the modified RTOG toxicity 
criteria weekly during RT and then at week 10, 12 and 18. 
The NCI CTCAE v4 scoring system was used pre-RT and at 
week 18. Patients were also asked to complete IPSS 
questionnaires at these times. Peak toxicity grade (G) was 
dichotomized: modified RTOG G0&1 (n=13) vs G2&3 (n=37) 
and NCI CTCAE v4 (G0 vs G1&2). The Mann Whitney U test 
was used to compare toxicity groups using a range of 
dosimetric descriptors for each GU pelvic structure. Data was 
analysed in SPSS, v22 (IBM SPSS, Armonk, NY). 
 
Results: 36 patients (72%) experienced a peak G2 RTOG acute 
toxicity and 1 patient G3. At week 18, half of the patients 
had no toxicity according to the NCI CTCAE v4. IPSS median 
and IQR at pre-RT and 18 weeks (n=45) were 5 (4-9) and 7 (5-
9) respectively.  
There were statistically significant differences in a number of 
dose surface parameters for WB and BT using NCI CTCAE v4. 
No urethral dose parameters related to toxicity (Table 1). 
There were no statistically significant results for RTOG peak 
toxicity.  
 
Conclusions: Our technique to produce the dose surface map 
of the BT has enhanced the dosimetric information available 
for analysis of acute GU toxicity. The results suggest that 
modifying dose surface parameters to WB and BT may impact 
on the incidence of acute toxicity.  
   
PO-0737   
Adjuvant hormone therapy in intermediate-high risk 
prostate cancer: LH-RH agonist versus anti-androgens 
J. Capuccini1, G. Macchia2, L. Giaccherini1, M. Zompatori3, G. 
Nuzzo2, G.C. Mattiucci4, M. Ntreta1, F. Deodato2, V. 
Valentini4, A.G. Morganti1 
1Policlinico Universitario S. Orsola Malpighi, Radiotherapy 
Department, Bologna, Italy  
2Fondazione Giovanni Paollo II Catholic University of Sacred 
Heart, Radiotherapy Department, Campobasso, Italy 
3Policlinico Universitario S. Orsola Malpighi, Radiology 
Department, Bologna, Italy  
4Catholic University of Sacred Heart, Radiation Oncology 
Unit, Roma, Italy  
 
Purpose/Objective: Adjuvant hormonal therapy (AHT) 
improves the prognosis in intermediate-high risk prostate 
cancer treated with radiotherapy (RT). Luteinizing hormone-
releasing hormone(LH -RH) agonist represent the standard 
AHT, although this treatment is associated with several 
adverse effect. An alternative treatment, not based on 
pharmacological castration, might be represented by high-
dose antiandrogens (bicalutamide 150 mg / day). However, 
data comparing this treatments in terms of disease control 
are lacking. Therefore, aim of this study was to compare the 
results of two groups of patients who underwent AHT with 
LH- RH analogues or with bicalutamide, respectively. 
Materials and Methods: We analyzed data from three 
different clinical trials in which patients received 
radiotherapy (RT) and AHT with LH- RH agonist or high doses 
bicalutamide. The therapeutic choice was based on the 
urologist and/or patient preferences. Biochemical 
recurrence-free survival (according to Phoenix criteria), local 
control, disease- free and overall survival were assessed using 
the Kaplan-Meier method. Survival curves were compared by 
log-rank test ( univariate analysis ) and Cox's Proportional 
Hazard Method (multivariate analysis , considering as 
covariates : stage , pretreatment Prostate Specific Antigen, 
Gleason Score, duration of AHT, RT doses delivered to the 
pelvic lymph nodes). Patients were classified according to 
the National Comprehensive Cancer Network 2014 risk. 
Results: A total of 315 patients were included in the analysis. 
The 5 year results at univariate analysis are reported in the 
table.Multivariate analysis confirmed the lack of impact of 
type of AHT on biochemical recurrence -free survival (p= 
0.758). 
Conclusions: 
The results of this study showed no significant differences in 
terms of biochemical and clinical outcomes among patients 
undergoing adjuvant AHT with LH -RH agonist or 
antiandrogen. Based on the lower toxicity profile of 
antiandrogens , further prospective studies comparing these 
two therapeutic alternatives appear justified.  
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Purpose/Objective: Radiation therapy (RT) after radical 
prostatectomy (RP) improves prognosis in patients with high 
risk prostate cancer. However 5-year biochemical recurrence-
free survival (bRFS) is only 75-80%. An advantage of 
hypofractionation is to reduce RT duration and to improve 
the probability of cure. However hypofractionation is 
potentially associated with an increased incidence of late 
toxicity, especially after RP. Data on efficacy and tolerability 
of hypofractionated RT in the postoperative setting are still 
lacking. Therefore, aim of this study is to compare two 
different trials using postoperative RT with conventional 
fractionation versus hypofractionation. 
Materials and Methods: In an observational study, 
postoperative RT was performed with three dimensional 
conformal radiotherapy (3DCRT) (Total dose: 70.2 Gy/1.8 Gy 
per fraction). In a fase I-II trial, postoperative RT was 
performed with intensity modulated radiotherapy (IMRT) 
using simultaneous integrated boost (SIB) technique (Total 
dose 62.5 Gy/2.5 Gy per fraction). In both trials, prophylactic 
nodal irradiation and/or adjuvant hormonotherapy were 
administered according to risk factors. bRFS (PSA < 0.2 
ng/ml), local control, disease-free-survival (DFS) and overall 
survival (OS) were analyzed using Kaplan-Meier method. A 
comparison of the survival curves was performed using long 
rank test (univariate analysis) or Cox Proportional Hazards 
Method (multivariate analysis; covariates: risk group, nodal 
irradiation and hormonotherapy duration). 
Results: Considering the two studies, 194 patients were 
enrolled. Three-year bRFS was 83.3% (pN0: 90.3% vs pN1: 
62.5%). The results are shown in Table 1. In terms of bRFS 
there was no statistical difference between the two series, 
even at multivariate analisys (p= 0.689). 
 
 
Conclusions: High dose adjuvant RT modulated based on risk 
factors (+/- prophylactic nodal irradiation, +/- adjuvant 
hormonotherapy) produced a better biochemical control 
compared to standard postoperative RT. Patients treated 
with IMRT-SIB technique showed a lower rate of acute and 
late gastrointestinal toxicity. 
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Purpose/Objective: Small bowel toxicity from external beam 
radiotherapy (EBRT) for prostate cancer is poorly predicted 
from current DVH based models. The dose absorbed by this 
mobile organ throughout a fractionated course of EBRT 
cannot easily be calculated from a single planning CT scan. 
Plasma levels of citrulline (an amino acid, secreted by the 
gut) is a putative biomarker of small bowel radiation induced 
damage and as such a decrease in levels may predict small 
bowel toxicity. In this prospective, clinical study, we 
explored the relationship between the change in plasma 
citrulline in relation to both gastrointestinal toxicity and 
small bowel dosimetry in patients receiving radical EBRT for 
prostate cancer.  
Materials and Methods: We recruited 15 patients treated 
with EBRT to either prostate only (n=6) or prostate and pelvis 
(n=9). Plasma citrulline levels were measured prior to 
radiotherapy and weekly during treatment and at 6 weeks, 3 
months and 6 months post EBRT. Bowel toxicity was assessed 
at the same time points using EPIC bowel summary scores. 
Small bowel dosimetry was calculated on a single pre-
treatment radiotherapy planning scan. 
Results: The strongest correlation between the fall in plasma 
citrulline levels from baseline and greatest bowel toxicity 
was observed after 3 weeks of radiotherapy (two tailed 
Spearman's rank test p=0.03). We further explored the ability 
of this week 3 plasma citrulline decrease to predict bowel 
toxicity up to one year post radiotherapy with two-tailed 
Spearman rank tests between radiotherapy week 3 citrulline 
change and EPIC bowel toxicity change. A strong predictive 
trend was noted with positive correlations at 6 weeks post 
radiotherapy (correlation co-efficient =0.594, p=0.025), 3 
months post radiotherapy (correlation co-efficient =0.534, 
p=0.060), 6 months post radiotherapy (correlation co-
efficient =0.606, p=0.037), 9 months post radiotherapy 
(correlation co-efficient =0.618, p=0.019) and 1 year post 
radiotherapy (correlation co-efficient =0.358, p=0.345). No 
significant correlation was found between changes in plasma 
citrulline levels or EPIC reported toxicity and the small bowel 
V15, dose to 1cm3, dose to 17cm3 or max point dose. 
Conclusions: Decreases in plasma citrulline after 3 weeks of 
pelvic EBRT may have the potential to predict small bowel 
toxicity in prostate cancer patients receiving radical external 
beam radiotherapy. Further study in a larger cohort is 
warranted. 
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